Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • biotechs

    Headshot of Sarah Theobald with text reading 'Healthcare communications trends in 2026'

    What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends

    By Sarah Theobald

    Amiculum

    - PMLiVE

    Does real-world use of AI in systematic literature reviews result in time and cost savings?

    By Manca Povsic and Emma Griffiths

    Amiculum

    Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

    Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

    By Emily Morton-West

    Amiculum

    Genesis giveaway of a minifigure

    Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

    Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...

    Genesis Research Group

    - PMLiVE

    Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

    New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

    BOLDSCIENCE

    - PMLiVE

    Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030

    [Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...

    Uniphar

    Streamlining European expansion for cell and gene therapies

    Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...

    Uniphar

    - PMLiVE

    Current CGT landscape and future outlook  

    What makes CGT unique  Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...

    Uniphar

    - PMLiVE

    Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals 

    This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...

    Uniphar

    - PMLiVE

    Navigating the complexities of launch preparation for Cell and Gene Therapy

    Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...

    Uniphar

    ECA webinar image

    ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

    On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...

    Genesis Research Group

    - PMLiVE

    Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

    Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...

    Uniphar

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links